Impact of body mass index on overall survival in patients with metastatic breast cancer.
BMI
Metastatic breast cancer
Obesity
Overall survival
Underweight
Journal
Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
14
07
2020
revised:
21
11
2020
accepted:
23
11
2020
pubmed:
12
12
2020
medline:
16
10
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC). The National ESME-MBC observational cohort includes all consecutive patients newly diagnosed with MBC between Jan 2008 and Dec 2016 in the 18 French comprehensive cancer centers. Of 22 463 patients in ESME-MBC, 12 999 women had BMI data available at MBC diagnosis. Median BMI was 24.9 kg/m Overweight and obesity are not associated with poorer outcomes in women with metastatic disease, while underweight appears as an independent adverse prognostic factor.
Sections du résumé
BACKGROUND
BACKGROUND
High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC).
METHODS
METHODS
The National ESME-MBC observational cohort includes all consecutive patients newly diagnosed with MBC between Jan 2008 and Dec 2016 in the 18 French comprehensive cancer centers.
RESULTS
RESULTS
Of 22 463 patients in ESME-MBC, 12 999 women had BMI data available at MBC diagnosis. Median BMI was 24.9 kg/m
CONCLUSION
CONCLUSIONS
Overweight and obesity are not associated with poorer outcomes in women with metastatic disease, while underweight appears as an independent adverse prognostic factor.
Identifiants
pubmed: 33307392
pii: S0960-9776(20)30220-4
doi: 10.1016/j.breast.2020.11.014
pmc: PMC7725947
pii:
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
16-24Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing interest V.D reports advisory boards from Roche, Genentech, Lilly, Pfizer, Astra Zeneca, MSD, Daiichi Sankyo and Seattle Genetics. PE-H reports research funding from Pfizer, Novartis E.B receive honoraria or consultation fees: AstraZeneca, BMS, Celgene, Clinigen, G1 Therapeutics, Hospira, Janssen, Mylan, OBI Pharma, Pfizer, Puma, Roche, Samsung; Receipt of grants/research supports: Amgen, HalioDX (Qiagen/Ipsogen), TEVA (Cephalon); Travel support: AstraZeneca, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz. A.G reports travel expenses, accommodation and registration meeting from Astra Zeneca, Roche, Pfizer, Novartis. P.C reports grants form Pfizer and Novartis, personal fees from Pfizer and Lilly, non-financial support from Pfizer. S.D. reports institutional fees and non-financial support from Roche/Genentech; grants, institutional fees and nonfinancial support from Pfizer; institutional fees and nonfinancial support from Puma; grants, institutional fees and non-financial support from AstraZeneca; grants, institutional fees and non-financial support from Novartis; institutional fees and non-financial support from Amgen. E.D reports travel expenses from Pfizer, Novartis and Amgen and boards from Novartis and Pfizer. The other authors declare that they have no conflict of interest to disclose.